We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 02, 2021

Cemiplimab Monotherapy for First-Line Treatment of Advanced NSCLC With PD-L1 of at Least 50%

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Cemiplimab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With PD-L1 of at Least 50%: A Multicentre, Open-Label, Global, Phase 3, Randomised, Controlled Trial
Lancet 2021 Feb 13;397(10274)592-604, A Sezer, S Kilickap, M Gümüş, I Bondarenko, M Özgüroğlu, M Gogishvili, HM Turk, I Cicin, D Bentsion, O Gladkov, P Clingan, V Sriuranpong, N Rizvi, B Gao, S Li, S Lee, K McGuire, CI Chen, T Makharadze, S Paydas, M Nechaeva, F Seebach, DM Weinreich, GD Yancopoulos, G Gullo, I Lowy, P Rietschel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading